ArticleInternational health2024
Persons 'never treated' in mass drug administration for lymphatic filariasis: identifying programmatic and research needs from a series of research review meetings 2020-2021.
Article in International health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 11 citations in OpenAlex.
- Prevalence and Determinants of Never Treatment During Mass Drug Administration for Lymphatic Filariasis: A Systematic Review and Meta-Analysis.Healthcare (Basel, Switzerland) · 2026Review
- Beneficiary feedback mechanisms: Exploring ways to systematically integrate community feedback in mass drug administration delivery for NTDs.PLoS neglected tropical diseases · 2026Article
- Article
- Impact of mass drug administration with Ivermectin, Diethylcarbamazine, and Albendazole in elimination of lymphatic filariasis in five districts of Nepal.PLOS global public health · 2026Article
- Semi-annual and annual mass drug administration of diethylcarbamazine and albendazole are equally effective regimens for eliminating lymphatic filariasis in Papua New Guinea.PLoS neglected tropical diseases · 2025Article
- Factors associated with low coverage in mass drug administration for schistosomiasis in mobile populations in mali: a cross-sectional study.BMC infectious diseases · 2025Article
- Epidemiological monitoring survey to assess the impact of mass drug administration with triple-drug regimen in lymphatic filariasis elimination programme in an endemic district in Southern India.PLoS neglected tropical diseases · 2025Article
- Integrated serological surveillance for neglected tropical diseases, vaccine-preventable diseases, and arboviruses in Samoa, 2018.Scientific reports · 2025Article
- Understanding the barriers and facilitators related to never treatment during mass drug administration among mobile and migrant populations in Mali: a qualitative exploratory study.BMJ global health · 2024Article
- New Tools and Nuanced Interventions to Accelerate Achievement of the 2030 Roadmap for Neglected Tropical Diseases.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 10 institutions in 5 countries.
Funding
Abstract
As neglected tropical disease programs rely on participation in rounds of mass drug administration (MDA), there is concern that individuals who have never been treated could contribute to ongoing transmission, posing a barrier to elimination. Previous research has suggested that the size and characteristics of the never-treated population may be important but have not been sufficiently explored. To address this critical knowledge gap, four meetings were held from December 2020 to May 2021 to compile expert knowledge on never treatment in lymphatic filariasis (LF) MDA programs. The meetings explored four questions: the number and proportion of people never treated, their sociodemographic characteristics, their infection status and the reasons why they were not treated. Meeting discussions noted key issues requiring further exploration, including how to standardize measurement of the never treated, adapt and use existing tools to capture never-treated data and ensure representation of never-treated people in data collection. Recognizing that patterns of never treatment are situation specific, participants noted measurement should be quick, inexpensive and focused on local solutions. Furthermore, programs should use existing data to generate mathematical models to understand what levels of never treatment may compromise LF elimination goals or trigger programmatic action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.